SEARCH:   Advanced

Blood, 15 May 2005, Vol. 105, No. 10, pp. 3817-3823. Prepublished online as a Blood First Edition Paper on February 1, 2005; DOI 10.1182/blood-2004-10-3920. This Article Full Text (PDF) All Versions of this Article: 2004-10-3920v1 105/10/3817    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by DECONINCK, E. Articles by COLOMBAT, P. Search for Related Content PubMed PubMed Citation Articles by DECONINCK, E. Articles by COLOMBAT, P. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted October 12, 2004 Accepted January 24, 2005 High dose therapy followed by autologous purged stem cell transplantation and doxorubicin based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS Eric DECONINCK, Charles FOUSSARD, Noel MILPIED, Philippe BERTRAND, Patrick MICHENET, Pascale CORNILLET-LEFEBVRE, Martine ESCOFFRE-BARBE, Herve MAISONNEUVE, Vincent DELWAIL, Remy GRESSIN, Eric LEGOUFFE, Jean-Pierre VILQUE, Bernard DESABLENS, Jerome JAUBERT, Jean-Francois RAMEE, Arash JENABIAN, Antoine THYSS, Annick LE POURHIET-LE MEVEL, Philippe TRAVADE, Roselyne DELEPINE, and Philippe COLOMBAT* Institut National de la Sante et de la Recherche Medicale U645, Universite de Besancon - Equipe d'accueil 2284 - Institut Federatif de Recherche 133, Etablissement Francais du Sang Bourgogne-Franche-Comte, Department of Hematology -University Hospital - Jean Minjoz Hospital, Besancon, Besancon, France Department of Hematology, University Hospital, Angers, France Department of Hematology, University Hospital of Nantes, Hotel Dieu, Nantes, France Department of Hematology and Biostatistics, University Hospital of Tours, Bretonneau Hospital, Tours, France Department of Pathology, Centre hospitalier, Orleans, France Department of Hematology and Cytogenetics, University Hospital, Reims, France Department of Hematology, University Hospital, Brest, France Department of Hematology, Centre Hospitalier, La Roche-sur-Yon, France Department of Hematology, University Hospital of Poitiers, Jean Bernard Hospital, Poitiers, France Department of Hematology, University Hospital, Grenoble, France Department of Hematology, University Hospital of Montpellier, Montpellier, France Department of Hematology, University Hospital, Reims, France Department of Hematology, University Hospital, Amiens, France Department of Hematology, University Hospital, Saint-Etienne, France Department of Hematology, Catherine de Sienne Clinic, Nantes, France Department of Hematology, Hopital Europeen Georges Pompidou, Paris, France Lacassagne Anticancer Center, Nice, France Gauduchot Anticancer Center, Nantes, France Department of Hematology, University Hospital, Clermont-Ferrand, France Department of Hematology, University Hospital, Tours, France * Corresponding author; email: colombat{at}med.univ-tours.fr. Doxorubicin based immunochemotherapy, with interferon, has been shown to improve survival in patients with advanced follicular lymphoma. High dose chemotherapy with stem cell support is effective in follicular lymphoma in relapse, but remains controversial as a first line therapy. In a randomized study using a purged autologous stem cell support, we compared these two approaches in patients with advanced follicular lymphoma. One hundred and seventy-two newly diagnosed advanced follicular lymphoma patients were randomly assigned either to an immunochemotherapy regimen (cyclophosphamide, doxorubicin, teniposide, prednisone, and interferon) or to a high dose therapy followed by purged autologous stem cell transplantation. Compared with the patients who received chemotherapy and interferon, patients treated with high-dose therapy had a higher response rate (69% vs. 81%, P = 0.045) and a longer median event-free survival (not reached vs. 45 months). This did not translate into a better survival rate due to an excess of secondary malignancies after transplantation. The Follicular Lymphoma Prognostic Index identified a sub-group of patients with a significant higher event-free survival rate after high-dose therapy. Autologous stem cell transplantation cannot be considered as the standard first-line treatment of follicular lymphoma for patients less than 60 years old with a high tumor burden. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: F. Morschhauser, M. Dreyling, A. Rohatiner, F. Hagemeister, and A. Bischof Delaloye Rationale for Consolidation to Improve Progression-Free Survival in Patients with Non-Hodgkin's Lymphoma: A Review of the Evidence Oncologist, October 1, 2009; 14(suppl_2): 17 - 29. [Abstract] [Full Text] [PDF] C. Gisselbrecht, J. Vose, A. Nademanee, A. M. Gianni, and A. Nagler Radioimmunotherapy for Stem Cell Transplantation in Non-Hodgkin's Lymphoma: In Pursuit of a Complete Response Oncologist, October 1, 2009; 14(suppl_2): 41 - 51. [Abstract] [Full Text] [PDF] A. Bischof Delaloye, P. S. Conti, C. Gisselbrecht, and S. A. Gregory Summary Oncologist, October 1, 2009; 14(suppl_2): 52 - 54. [Full Text] [PDF] M. Kornacker, J. Stumm, C. Pott, S. Dietrich, S. Sussmilch, M. Hensel, M. Nickelsen, M. Witzens-Harig, M. Kneba, N. Schmitz, et al. Characteristics of relapse after autologous stem-cell transplantation for follicular lymphoma: a long-term follow-up Ann. Onc., April 1, 2009; 20(4): 722 - 728. [Abstract] [Full Text] [PDF] E. Gyan, C. Foussard, P. Bertrand, P. Michenet, S. Le Gouill, C. Berthou, H. Maisonneuve, V. Delwail, R. Gressin, P. Quittet, et al. High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years Blood, January 29, 2009; 113(5): 995 - 1001. [Abstract] [Full Text] [PDF] G. Salles, N. Mounier, S. de Guibert, F. Morschhauser, C. Doyen, J.-F. Rossi, C. Haioun, P. Brice, B. Mahe, R. Bouabdallah, et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study Blood, December 15, 2008; 112(13): 4824 - 4831. [Abstract] [Full Text] [PDF] F. Morschhauser, J. Radford, A. Van Hoof, U. Vitolo, P. Soubeyran, H. Tilly, P. C. Huijgens, A. Kolstad, F. d'Amore, M. G. Diaz, et al. Phase III Trial of Consolidation Therapy With Yttrium-90-Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma J. Clin. Oncol., November 10, 2008; 26(32): 5156 - 5164. [Abstract] [Full Text] [PDF] M. Bendandi Aiming at a Curative Strategy for Follicular Lymphoma CA Cancer J Clin, September 1, 2008; 58(5): 305 - 317. [Abstract] [Full Text] [PDF] F. R. Appelbaum Hematopoietic Cell Transplantation for Non-Hodgkin's Lymphoma: Yesterday, Today, and Tomorrow J. Clin. Oncol., June 20, 2008; 26(18): 2927 - 2929. [Full Text] [PDF] J. P. Plastaras, E. Glatstein, and S. J. Schuster Commentary: Let the Tail Wag the Dog: The Case for Radioimmunotherapy of Low-Grade Follicular Lymphoma Oncologist, June 1, 2008; 13(6): 655 - 656. [Full Text] [PDF] F. Buchegger, O. W. Press, A. B. Delaloye, and N. Ketterer Radiolabeled and Native Antibodies and the Prospect of Cure of Follicular Lymphoma Oncologist, June 1, 2008; 13(6): 657 - 667. [Abstract] [Full Text] [PDF] M. Ladetto, F. De Marco, F. Benedetti, U. Vitolo, C. Patti, A. Rambaldi, A. Pulsoni, M. Musso, A. M. Liberati, A. Olivieri, et al. Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage Blood, April 15, 2008; 111(8): 4004 - 4013. [Abstract] [Full Text] [PDF] A. Z.S. Rohatiner, L. Nadler, A. J. Davies, J. Apostolidis, D. Neuberg, J. Matthews, J. G. Gribben, P. M. Mauch, T. A. Lister, and A. S. Freedman Myeloablative Therapy With Autologous Bone Marrow Transplantation for Follicular Lymphoma at the Time of Second or Subsequent Remission: Long-Term Follow-Up J. Clin. Oncol., June 20, 2007; 25(18): 2554 - 2559. [Abstract] [Full Text] [PDF] J. G. Gribben How I treat indolent lymphoma Blood, June 1, 2007; 109(11): 4617 - 4626. [Abstract] [Full Text] [PDF] M. Herold, A. Haas, S. Srock, S. Neser, K. H. Al-Ali, A. Neubauer, G. Dolken, R. Naumann, W. Knauf, M. Freund, et al. Rituximab Added to First-Line Mitoxantrone, Chlorambucil, and Prednisolone Chemotherapy Followed by Interferon Maintenance Prolongs Survival in Patients With Advanced Follicular Lymphoma: An East German Study Group Hematology and Oncology Study J. Clin. Oncol., May 20, 2007; 25(15): 1986 - 1992. [Abstract] [Full Text] [PDF] S. Vigouroux, M. Michallet, R. Porcher, M. Attal, L. Ades, M. Bernard, D. Blaise, R. Tabrizi, F. Garban, J.-P. Cassuto, et al. Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC) Haematologica, May 1, 2007; 92(5): 627 - 634. [Abstract] [Full Text] [PDF] A. K. Gopal, J. G. Rajendran, T. A. Gooley, J. M. Pagel, D. R. Fisher, S. H. Petersdorf, D. G. Maloney, J. F. Eary, F. R. Appelbaum, and O. W. Press High-Dose [131I]Tositumomab (anti-CD20) Radioimmunotherapy and Autologous Hematopoietic Stem-Cell Transplantation for Adults >= 60 Years Old With Relapsed or Refractory B-Cell Lymphoma J. Clin. Oncol., April 10, 2007; 25(11): 1396 - 1402. [Abstract] [Full Text] [PDF] C Nickenig, M Dreyling, E Hoster, W-D Ludwig, B Dorken, M Freund, C Huber, A Ganser, L Trumper, R Forstpointner, et al. Initial chemotherapy with mitoxantrone, chlorambucil, prednisone impairs the collection of stem cells in patients with indolent lymphomas--results of a randomized comparison by the German Low-Grade Lymphoma Study Group Ann. Onc., January 1, 2007; 18(1): 136 - 142. [Abstract] [Full Text] [PDF] K. van Besien Autologous transplantation for follicular lymphoma? Not too soon! Blood, October 15, 2006; 108(8): 2496 - 2497. [Full Text] [PDF] C. Sebban, N. Mounier, N. Brousse, C. Belanger, P. Brice, C. Haioun, H. Tilly, P. Feugier, R. Bouabdallah, C. Doyen, et al. Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA) Blood, October 15, 2006; 108(8): 2540 - 2544. [Abstract] [Full Text] [PDF] T. Kober, H. Hulsewede, J. Bohlius, and A. Engert Fourth biannual report of the Cochrane Haematological Malignancies Group. J Natl Cancer Inst, April 19, 2006; 98(8): E1 - E1. [Full Text] J. R. Brown and A. S. Freedman In Reply: J. Clin. Oncol., November 1, 2005; 23(31): 8121 - 8122. [Full Text] [PDF] G. Lenz, M. Dreyling, M. Unterhalt, and W. Hiddemann In Reply: J. Clin. Oncol., September 1, 2005; 23(25): 6264 - 6266. [Full Text] [PDF]

	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020